Dimensional Fund Advisors LP Has $529,000 Stock Holdings in Sanara MedTech Inc. (NASDAQ:SMTI)

Dimensional Fund Advisors LP increased its position in shares of Sanara MedTech Inc. (NASDAQ:SMTI) by 116.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,925 shares of the company’s stock after acquiring an additional 8,567 shares during the period. Dimensional Fund Advisors LP owned about 0.18% of Sanara MedTech worth $529,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Fifth Third Bancorp acquired a new stake in Sanara MedTech in the fourth quarter valued at approximately $898,000. Barclays PLC boosted its position in Sanara MedTech by 323.0% in the third quarter. Barclays PLC now owns 5,731 shares of the company’s stock valued at $174,000 after buying an additional 4,376 shares in the last quarter. Renaissance Technologies LLC boosted its position in Sanara MedTech by 152.9% in the fourth quarter. Renaissance Technologies LLC now owns 35,400 shares of the company’s stock valued at $1,175,000 after buying an additional 21,400 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Sanara MedTech by 234.5% in the fourth quarter. JPMorgan Chase & Co. now owns 13,574 shares of the company’s stock valued at $451,000 after buying an additional 9,516 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Sanara MedTech by 24.0% in the fourth quarter. Bank of New York Mellon Corp now owns 13,054 shares of the company’s stock valued at $433,000 after buying an additional 2,528 shares in the last quarter. Institutional investors and hedge funds own 8.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on SMTI. HC Wainwright raised their target price on shares of Sanara MedTech from $51.00 to $53.00 and gave the company a “buy” rating in a research report on Thursday. Cantor Fitzgerald restated an “overweight” rating and issued a $46.00 target price on shares of Sanara MedTech in a research report on Wednesday, March 26th.

Sanara MedTech Price Performance

Shares of NASDAQ:SMTI opened at $31.50 on Friday. The firm has a market cap of $279.97 million, a PE ratio of -31.82 and a beta of 1.38. The firm’s fifty day moving average is $31.06 and its 200-day moving average is $33.45. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.02 and a current ratio of 2.23. Sanara MedTech Inc. has a 52 week low of $25.86 and a 52 week high of $39.08.

Sanara MedTech (NASDAQ:SMTI) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). The business had revenue of $23.43 million for the quarter, compared to analyst estimates of $23.48 million. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%. Sell-side analysts predict that Sanara MedTech Inc. will post -1.1 earnings per share for the current year.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.